Xtant Medical (NYSEAMERICAN:XTNT – Get Free Report) announced its quarterly earnings results on Tuesday. The medical device company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.02), Zacks reports. The firm had revenue of $27.94 million for the quarter. Xtant Medical had a negative net margin of 15.45% and a negative return on equity of 37.07%. Xtant Medical updated its FY 2024 guidance to EPS.
Xtant Medical Trading Down 4.0 %
Shares of NYSEAMERICAN:XTNT traded down $0.02 on Friday, hitting $0.43. The company had a trading volume of 43,061 shares, compared to its average volume of 101,632. Xtant Medical has a 1 year low of $0.43 and a 1 year high of $1.45. The company has a current ratio of 2.12, a quick ratio of 1.01 and a debt-to-equity ratio of 0.42. The stock has a market cap of $59.89 million, a price-to-earnings ratio of -3.31 and a beta of 0.39.
Analyst Upgrades and Downgrades
Separately, Craig Hallum set a $1.50 target price on shares of Xtant Medical and gave the stock a “buy” rating in a research report on Friday, October 18th.
Xtant Medical Company Profile
Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.
Read More
- Five stocks we like better than Xtant Medical
- Compound Interest and Why It Matters When Investing
- Top-Performing Non-Leveraged ETFs This Year
- How to invest in marijuana stocks in 7 steps
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
- Stock Market Upgrades: What Are They?
- Freshworks Stock Soars 50% – Is This the Perfect Entry Point?
Receive News & Ratings for Xtant Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xtant Medical and related companies with MarketBeat.com's FREE daily email newsletter.
